A Safety and Efficacy Study of Dissolve™ in Treatment of Coronary Small Vessel Disease

NACompletedINTERVENTIONAL
Enrollment

277

Participants

Timeline

Start Date

June 20, 2018

Primary Completion Date

January 10, 2020

Study Completion Date

April 15, 2024

Conditions
Coronary Small Vessel Disease
Interventions
DEVICE

Cohort A: Dissolve™

Dissolve™ are to be used in the trial

DEVICE

Cohort A: Resolute™ Integrity

Resolute™ Integrity are to be used in the trial

DEVICE

Cohort B: Dissolve™-2.00mm

Dissolve™ are to be used in the trial

Trial Locations (15)

Unknown

Beijing Anzhen Hospital, Capital Medical University, Beijing

Beijing Friendship Hospital, Capital Medical University, Beijing

Beijing Hospital, Beijing

Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing

Peking Union Medical College Hospital, Beijing

Peking University People's Hospital, Capital Medical University, Beijing

Xiangya Hospital of Central South University, Changsha

West China Hospital, Sichuan University, Chengdu

The First Affiliated Hospital of Dalian Medical University, Dalian

The Second Affiliated Hospital of Dalian Medical University, Dalian

General Hospital of Daqing Oil Field, Daqing

Sir Run Run Shaw Hospital, Zhejiang University School of medicine, Hangzhou

Union Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan

General Hospital of Ningxia Medical University, Yinchuan

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors
collaborator

Core Medical (Beijing) Co., Ltd.

OTHER

lead

DK Medical Technology (Suzhou) Co., Ltd.

INDUSTRY

NCT03376646 - A Safety and Efficacy Study of Dissolve™ in Treatment of Coronary Small Vessel Disease | Biotech Hunter | Biotech Hunter